MDGL
Madrigal Pharmaceuticals Inc
NASDAQ: MDGL · HEALTHCARE · BIOTECHNOLOGY
$517.39
-0.23% today
Updated 2026-04-30
Market cap
$11.96B
P/E ratio
—
P/S ratio
12.48x
EPS (TTM)
$-12.87
Dividend yield
—
52W range
$265 – $615
Volume
0.4M
Madrigal Pharmaceuticals Inc (MDGL) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-38.2%
Last 4 quarters
Revenue YoY growth
+210.8%
Most recent quarter
EPS YoY growth
+5.2%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-1.2%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-11.5%
2026-02-19
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-19 | $-2.57 | -325.6% | $491.49 | $435.01 | -11.5% |
| 2025-10-29 | $-4.96 | -47.5% | $429.18 | $427.52 | -0.4% |
| 2025-08-05 | $-1.90 | +47.7% | $312.11 | $338.11 | +8.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.60 | $-2.57 | -325.6% | $321.08M | +210.8% |
| 2025-09-30 | $-3.36 | $-4.96 | -47.5% | $287.27M | +362.0% |
| 2025-06-30 | $-3.63 | $-1.90 | +47.7% | $212.80M | +1353.8% |
| 2025-03-31 | $-6.28 | $-3.32 | +47.1% | $137.25M | — |
| 2024-12-31 | $-4.12 | $-2.71 | +34.3% | $103.32M | +13318.2% |
| 2024-09-30 | $-6.91 | $-4.92 | +28.8% | $62.17M | — |
| 2024-06-30 | $-7.53 | $-7.10 | +5.7% | $14.64M | — |
| 2024-03-31 | $-6.28 | $-7.38 | -17.5% | — | — |
| 2023-12-31 | $-5.28 | $-5.68 | -7.6% | $770000.00 | — |
| 2023-09-30 | $-4.93 | $-5.34 | -8.3% | — | — |
| 2023-06-30 | $-4.58 | $-4.69 | -2.4% | — | — |
Frequently asked questions
Has Madrigal Pharmaceuticals Inc beaten earnings estimates?
Madrigal Pharmaceuticals Inc has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -38.2% over the last 4 quarters.
How does MDGL stock react to earnings?
MDGL stock has moved an average of -1.2% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Madrigal Pharmaceuticals Inc's revenue growth rate?
Madrigal Pharmaceuticals Inc reported year-over-year revenue growth of +210.8% in its most recent quarter, with EPS growing +5.2% year-over-year.